- life sciences/pharma sector
-
2nd Annual Drug Development for Neurodegenerative Diseases
Advances in Drug Development for Neurodegenerative Diseases and Expediting Discovery through Novel Compounds and Sound Clinical Trials
Event Date: 18-19 May 2010
Location: Hilton Boston Financial District, Boston MA, USA
- key conference topics
-
- Regeneration in NDD through Neurogenesis
- Revolutionizing Drug Discovery & Rehabilitation Medicine by Applying Robotics and Information Technology
- Neuroimaging Biomarker Developments
- Hormesis Applications for Neurodegenerative Diseases
- Allosteric Modulation of Gamma-Secretase Reduces Beta-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease
- conference focus
-
Continuing its Drug Development for NDD in Pharma series marcus evans invites you to attend the 2nd Annual Drug Development fo Continuing its Drug Development for NDD in Pharma series marcus evans invites you to attend the 2nd Annual Drug Development for Neurodegenerative Diseases Conference. More than 18 industry professionals from leading pharmaceutical and biopharma companies will provide valuable insights on innovations within pre-clinical studies, clinical trial designs, biomarker discoveries and target identification for therapeutic and drug discovery journey and will discuss the latest developments in drug discovery for neurodegenerative diseases.
Hear from your peers first hand on why CNS therapies are helping fuel the rapid advancement of small-molecule drug development. Determine why there is a need to start CNS research and development early with new identifications of several disease-specific genes and proteins, which offer hope for new curative therapies for NDD. The challenges faced in today’s neurodegenerative drug discovery process are big, but significant advances have taken place and the race is on to find the next blockbuster therapy.
This is not a trade show; our Drug Development for NDD series is targeted at a focused group of 50-60 senior level executives to maintain an intimate atmosphere for the delegates and speakers. Since we are not a vendor driven conference, the higher level focus allows the delegates to network with their industry peers and speakers.
LinkedIn Group
Join our Drug Development for Neurodegenerative Diseases LinkedIn Group to be able to start networking with other industry leaders before and after the conference.